Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22257Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Kiorpelidou, D. | en |
| dc.contributor.author | Tsiouri, G. | en |
| dc.contributor.author | Gaitanis, G. | en |
| dc.contributor.author | Akritidis, N. | en |
| dc.contributor.author | Bassukas, I. D. | en |
| dc.date.accessioned | 2015-11-24T19:23:09Z | - |
| dc.date.available | 2015-11-24T19:23:09Z | - |
| dc.identifier.issn | 1365-2230 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22257 | - |
| dc.rights | Default Licence | - |
| dc.subject | Antibodies, Monoclonal/*adverse effects | en |
| dc.subject | Drug Eruptions/*pathology | en |
| dc.subject | Humans | en |
| dc.subject | Immunosuppressive Agents/*adverse effects | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Psoriasis/*drug therapy | en |
| dc.subject | Recurrence | en |
| dc.subject | Severity of Illness Index | en |
| dc.subject | Thrombocytopenia/chemically induced/*pathology | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Efalizumab-induced thrombocytopenia: report of relapse after re-administration | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | 10.1111/j.1365-2230.2009.03697.x | - |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/20055866 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1111/j.1365-2230.2009.03697.x/asset/j.1365-2230.2009.03697.x.pdf?v=1&t=h0oz3lnc&s=282bd0881b483cff704559ad53da6c54f73f35ec | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2009 | - |
| heal.abstract | Although a reversible, sometimes severe, drug-induced thrombocytopenia is a recognized adverse drug reaction (ADR) in patients with psoriasis treated with efalizumab, definite proof for the association of thrombocytopenia with efalizumab is still lacking (currently level II evidence for ADR). We report a patient with psoriasis who had two episodes of reversible thrombocytopenia during efalizumab; the first occurred 5 months after introduction of the medication and the second 4 months after re-introduction of efalizumab for relapsing psoriasis. The development of a second episode of thrombocytopenia on re-exposure to efalizumab provides, for the first time in the literature to our knowledge, definite (level I) ADR evidence for efalizumab-induced thrombocytopenia. | en |
| heal.journalName | Clin Exp Dermatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Kiorpelidou-2009-Efalizumab-induced t.pdf | 53.84 kB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
